Passage Bio to Report Third Quarter 2020 Financial Results on November 10, 2020
November 04 2020 - 7:00AM
Passage Bio, Inc. (NASDAQ: PASG), a genetic medicines company
focused on developing transformative therapies for rare, monogenic
central nervous system disorders, today announced that it will host
a conference call and live webcast at 8:30 a.m. ET on Tuesday,
November 10, 2020 to report its third quarter 2020 financial
results and discuss recent business highlights.
To access the live conference call, please dial 833-528-0605
(domestic) or 830-221-9711 (international) and refer to conference
ID 8478507. A live audio webcast of the event will be available on
the Investors & Media section of Passage Bio’s website at
investors.passagebio.com. The archived webcast will be available on
Passage Bio's website approximately two hours after the completion
of the event and for 30 days following the call.
About Passage BioAt Passage Bio (Nasdaq: PASG),
we are on a mission to provide life-transforming gene therapies for
patients with rare, monogenic CNS diseases that replace their
suffering with boundless possibility, all while building lasting
relationships with the communities we serve. Based in Philadelphia,
PA, our company has established a strategic collaboration and
licensing agreement with the renowned University of Pennsylvania’s
Gene Therapy Program to conduct our discovery and IND-enabling
preclinical work. This provides our team with unparalleled access
to a broad portfolio of gene therapy candidates and future gene
therapy innovations that we then pair with our deep clinical,
regulatory, manufacturing and commercial expertise to rapidly
advance our robust pipeline of optimized gene therapies into
clinical testing. As we work with speed and tenacity, we are always
mindful of patients who may be able to benefit from our therapies.
More information is available at www.passagebio.com.
For further information, please contact:
Investors:Sarah McCabe and Zofia MitaStern Investor Relations,
Inc.212-362-1200sarah.mccabe@sternir.com zofia.mita@sternir.com
Media:Gwen FisherPassage
Bio215.407.1548gfisher@passagebio.com
Passage Bio (NASDAQ:PASG)
Historical Stock Chart
From Sep 2024 to Oct 2024
Passage Bio (NASDAQ:PASG)
Historical Stock Chart
From Oct 2023 to Oct 2024